Cybin Future Growth
Future criteria checks 3/6
Cybin is forecast to grow earnings and revenue by 58.7% and 65.6% per annum respectively. EPS is expected to grow by 58.1% per annum. Return on equity is forecast to be -75.4% in 3 years.
Key information
58.7%
Earnings growth rate
58.1%
EPS growth rate
| Pharmaceuticals earnings growth | 18.3% |
| Revenue growth rate | 65.6% |
| Future return on equity | -75.4% |
| Analyst coverage | Low |
| Last updated | 27 Sep 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 3/31/2027 | 251 | 152 | -20 | -76 | 4 |
| 3/31/2026 | N/A | -106 | -110 | -89 | 4 |
| 3/31/2025 | N/A | -75 | -79 | -79 | 4 |
| 6/30/2024 | N/A | -78 | -86 | -85 | N/A |
| 3/31/2024 | N/A | -78 | -70 | -69 | N/A |
| 12/31/2023 | N/A | -70 | -60 | -59 | N/A |
| 9/30/2023 | N/A | -51 | -45 | -44 | N/A |
| 6/30/2023 | N/A | -49 | -50 | -47 | N/A |
| 3/31/2023 | N/A | -47 | -51 | -47 | N/A |
| 12/31/2022 | N/A | -52 | -50 | -46 | N/A |
| 9/30/2022 | N/A | -58 | -52 | -48 | N/A |
| 6/30/2022 | N/A | -66 | -48 | -47 | N/A |
| 3/31/2022 | N/A | -68 | -46 | -45 | N/A |
| 12/31/2021 | N/A | -63 | -43 | -42 | N/A |
| 9/30/2021 | N/A | -58 | -38 | -38 | N/A |
| 6/30/2021 | N/A | -43 | -27 | -26 | N/A |
| 3/31/2021 | 1 | -32 | -19 | -19 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: R7E is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.8%).
Earnings vs Market: R7E is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: R7E is expected to become profitable in the next 3 years.
Revenue vs Market: R7E is forecast to have no revenue next year.
High Growth Revenue: R7E is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: R7E is forecast to be unprofitable in 3 years.